Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BDSX 
Biodesix Inc (BDSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BDSX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $35
1 Year Target Price $35
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 726.32% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10B USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 6 | Beta 1 | 52 Weeks Range 0.17 - 8.71 | Updated Date 09/15/2025 |
52 Weeks Range 0.17 - 8.71 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -53.66% | Operating Margin (TTM) -48.42% |
Management Effectiveness
Return on Assets (TTM) -20.81% | Return on Equity (TTM) -219.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1151456406 | Price to Sales(TTM) 14.37 |
Enterprise Value 1151456406 | Price to Sales(TTM) 14.37 | ||
Enterprise Value to Revenue 15.04 | Enterprise Value to EBITDA -2.72 | Shares Outstanding 146632992 | Shares Floating 63841229 |
Shares Outstanding 146632992 | Shares Floating 63841229 | ||
Percent Insiders 51.24 | Percent Institutions 22.86 |
Upturn AI SWOT
Biodesix Inc
Company Overview
History and Background
Biodesix, Inc. was founded in 2005. It is a molecular diagnostics company focused on lung disease. Initially focused on proteomics, it has expanded its offerings to include genomics and artificial intelligence-based solutions.
Core Business Areas
- Lung Diagnostic Tests: Develops and commercializes diagnostic tests for lung cancer and other lung diseases.
- Research and Development: Conducts research to develop new diagnostic and prognostic tests.
- Services: Offers services to biopharmaceutical companies to support drug development.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other executive officers. The organizational structure is based on functional departments such as R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Nodify XL2: A blood-based test used to improve lung nodule risk assessment. It aims to reduce unnecessary invasive procedures and identify those that need diagnostic intervention. Market share data is not available in the requested format. Competitors include Veracyte (VCYT), Castle Biosciences (CSTL).
- LungStrat Dx Genomic Classifier: A test to predict response to immunotherapy in advanced lung cancer patients. Market share data is not available in the requested format. Competitors include Guardant Health (GH), Foundation Medicine (owned by Roche).
- GeneStrat NGS: A blood-based, comprehensive genomic profiling test for lung cancer. Market share data is not available in the requested format. Competitors include Guardant Health (GH), Foundation Medicine (owned by Roche).
- Pulmonary Function Testing (PFT): Assessment of lung function to help diagnosis of respiratory diseases.
Market Dynamics
Industry Overview
The molecular diagnostics market is growing due to increasing prevalence of diseases, advancements in technology, and demand for personalized medicine.
Positioning
Biodesix is positioned as a company focused on lung disease diagnostics. It aims to differentiate itself through innovative tests and strategic partnerships.
Total Addressable Market (TAM)
The TAM for lung cancer diagnostics is estimated to be billions of dollars. Biodesix is positioned to capture a share of this market through its comprehensive suite of diagnostic tests and its focus on precision medicine.
Upturn SWOT Analysis
Strengths
- Specialized focus on lung disease
- Proprietary technology platforms
- Comprehensive suite of diagnostic tests
- Strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on key products
- Competition from larger diagnostic companies
- Requires regulatory approvals
Opportunities
- Expanding into new markets
- Developing new diagnostic tests
- Partnering with biopharmaceutical companies
- Acquiring complementary technologies
Threats
- Regulatory changes
- Competition from established players
- Reimbursement challenges
- Technological advancements rendering current tests obsolete
Competitors and Market Share
Key Competitors
- VCYT
- GH
- CSTL
Competitive Landscape
Biodesix faces competition from larger, more established diagnostic companies. It aims to differentiate itself through its focus on lung disease and its proprietary technology platforms.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the adoption of its diagnostic tests and strategic partnerships.
Future Projections: Future growth is expected to be driven by new product launches and expansion into new markets. Analyst estimates are needed to provide specific projections.
Recent Initiatives: Recent initiatives include the launch of new diagnostic tests and partnerships with biopharmaceutical companies.
Summary
Biodesix is a molecular diagnostics company focused on lung disease with proprietary tests and technologies. Key strengths include its disease-specific focus, while weaknesses are competition and limited resources. Opportunities exist in market expansion and new products, but regulatory changes and reimbursement pose threats. The company is still considered to be in the growth stage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodesix Inc
Exchange NASDAQ | Headquaters Louisville, CO, United States | ||
IPO Launch date 2020-10-28 | President, CEO & Director Mr. Scott Hutton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 273 | Website https://www.biodesix.com |
Full time employees 273 | Website https://www.biodesix.com | ||
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.